NEW YORK (GenomeWeb) – The American Society of Clinical Oncology published revised early-stage breast cancer guidelines today that feature a focused update recommending Agendia's MammaPrint for guiding treatment decisions in early stage breast cancer patients with 1-to-3 positive lymph nodes.
According to the company, the revision is the fourth this year regarding MammaPrint, and is supported by data from the randomized, prospective, Phase III MINDACT trial, which was published last year.
Appearing in the Journal of Clinical Oncology, the ASCO guideline update represents the first recommendation by the association of a genomic test to guide the withholding of chemotherapy for lymph node-positive patients. Agendia said that the decision comes on the back of data from MINDACT that demonstrates the test can identify patients from among this otherwise high-risk group who actually have a good prognosis and in whom adjuvant chemotherapy would offer little additional benefit.
However, the update also notes that patients "should be informed that a benefit of chemotherapy cannot be excluded, particularly in patients with greater than one involved lymph node."
Agendia Chief Medical Officer William Audeh said in a statement that the ASCO guidelines panel affirmed the utility of MammaPrint in achieving the goal of reducing overtreatment in higher-risk patients.
"This is the second guideline update for MammaPrint in three weeks," Audeh added. "Based on MINDACT, both ASCO and the St. Gallen panel have now endorsed this test for both lymph-node negative and lymph node positive patients. Indeed, each of the four guidelines which included a review of the published findings of this unique trial so far this year have added or expanded their recommendation of MammaPrint."